Yannuo Pharmaceutical is a high-tech enterprise focused on pioneering advanced therapies in oncology, contrast agents, and anesthesia through innovative drug delivery platforms. Established in 2015, the company specializes in the research and development of complex injections, operating three main drug research and development technology platforms: liposomes, nanoparticles, and microspheres.
Leveraging these advanced drug delivery technologies, Yannuo Pharmaceutical concentrates on addressing clinical needs by researching and developing small molecule drugs, nucleic acid drugs, peptides, and protein drugs. With a commitment to further development and industrialization, the company focuses on therapeutic areas such as tumor treatment, contrast agents, anesthesia, and pain management.
The most recent investment in Yannuo Pharmaceutical was a Series A investment on July 7, 2023. The funding round involved investment from Zhejiang Huahai Pharmaceutical and Zhejiang Starry Pharmaceutical, indicating the interest and support of established players in the pharmaceutical industry.
Overall, Yannuo Pharmaceutical demonstrates a strong focus on leveraging advanced drug delivery technologies to address critical clinical needs in oncology and anesthesia, positioning it as an innovative player in the biotechnology and pharmaceutical industries.
